mercaptopurine

mercaptopurine /mer·cap·to·pur·ine/ (6-MP) (mer-kap″to-pūr´ēn) a sulfur-containing purine analogue, used as an antineoplastic and as an immunosuppressant.

---

mer·cap·to·pu·rine (mr-kpt-pyrn)

n.

A purine analog that acts as an antimetabolite by interfering with purine synthesis, used primarily in the treatment of acute leukemia.

---

mercaptopurine

[mərkap′təpyo̅o̅′rēn]

an antineoplastic and immunosuppressive; a purine antimetabolite. Also called 6-mercaptopurine (6-MP).

indications It is prescribed in the treatment of malignant neoplastic diseases, especially as maintenance therapy for acute lymphocytic leukemia.

contraindication Known hypersensitivity to this drug prohibits its use.

adverse effects Among the more severe adverse effects are bone marrow depression and acute GI disturbances, including nausea, vomiting, diarrhea, and stomatitis.

---

mercaptopurine [mer-kap″to-pu´rēn]

a purine analogue in which sulfur replaces the oxygen atom of purine; it is used as an antineoplastic agent primarily for treatment of acute lymphoblastic leukemia. It is also used an immunosuppressant in the treatment of Crohn's disease and ulcerative colitis. Called also 6-mercaptopurine and 6-MP.

---

mercaptopurine (6-MP),

n brand name: Purinethol;
drug class: antineoplastic-antimetabolite;
action: inhibits purine metabolism at multiple sites, which inhibits DNA and RNA synthesis;
uses: chronic myelocytic leukemia, acute lymphoblastic leukemia in children, acute myelogenous leukemia.

---

mercaptopurine, 6-mercaptopurine

an antimetabolite that acts by blocking purine synthesis; used as an antineoplastic agent, primarily in the treatment of leukemia and lymphosarcoma.

---

mercaptopurine (6-mercaptopurine, 6-MP) Warning - Hazardous drug!

Purinethol, Puri-Nethol (UK)

Pharmacologic class: Antimetabolite

Therapeutic class: Antineoplastic

Pregnancy risk category D

FDA Boxed Warning

• Don't give drug unless diagnosis of acute lymphatic leukemia is confirmed and responsible physician knows how to assess response to chemotherapy.

Action

Inhibits DNA and RNA synthesis, suppressing growth of certain cancer cells

Availability

Tablets: 50 mg

⊘Indications and dosages

➣ Acute lymphatic, myelogenous, or myelomonocytic leukemia

Adults and children: 2.5 mg/kg/day P.O. as a single dose, increased to 5 mg/kg/day after 4 weeks if response inadequate or if no toxicity occurs. On complete hematologic remission, give maintenance dosage of 1.5 to 2.5 mg/kg/day P.O. as a single dose (combined with other agents as prescribed).

Contraindications

• Hypersensitivity to drug or its components
• Prior resistance to drug or thioguanine
• Breastfeeding

Precautions

Use cautiously in:
• renal or hepatic impairment
• decreased platelet or neutrophil counts after chemotherapy or radiation
• pregnant patients.

Administration

• Follow facility protocols regarding proper handling and disposal of drug.
☞ Don't handle drug if you're pregnant.
• Be aware that total daily dosage is calculated to nearest multiple of 25 mg and given once daily.
☞ Withdraw drug immediately if white blood cell (WBC) or platelet count falls rapidly or steeply.

Route	Onset	Peak	Duration
P.O.	Unknown	2 hr	Unknown

Adverse reactions

GI: nausea, vomiting, anorexia, diarrhea, GI ulcers, painful oral ulcers, pancreatitis

Hematologic: anemia, leukopenia , thrombocytopenia

Hepatic: jaundice, hepatotoxicity

Metabolic: hyperuricemia

Skin: rash, hyperpigmentation

Interactions

Drug-drug. Allopurinol (more than 300 mg), aminosalicylate derivatives (mesalazine, olsalazine, sulfasalazine): increased bone marrow depression

Warfarin: decreased anticoagulant effect

Drug-diagnostic tests . Hemoglobin, platelets, red blood cells, uric acid, WBCs: increased values

Patient monitoring

☞ Watch for signs and symptoms of hepatotoxicity.
• Monitor weekly CBC with white cell differential and platelet count.
• Assess bone marrow aspiration and biopsy results, as necessary, to aid assessment of disease progression, resistance to therapy, and drug-induced marrow hypoplasia.
• Monitor serum uric acid level.
• Evaluate fluid intake and output.
• Monitor liver function tests and bilirubin level weekly at start of therapy, then monthly.

Patient teaching

☞ Instruct patient to immediately report fever, sore throat, increased bleeding or bruising, or signs or symptoms of liver problems (right-sided abdominal pain, yellowing of skin or eyes, nausea, vomiting, clay-colored stools, or dark urine).
• Advise both male and female patients to use reliable contraception.
• Encourage patient to maintain adequate fluid intake.
• Caution patient not to get vaccinations without consulting prescriber.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.